Moolec Science (MLEC) & Its Rivals Head to Head Analysis

Moolec Science (NASDAQ:MLEC) is one of 494 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Moolec Science to related businesses based on the strength of its earnings, dividends, profitability, analyst recommendations, risk, institutional ownership and valuation.

Institutional & Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.2% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Moolec Science has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 1.23, suggesting that their average stock price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Moolec Science and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	981	2797	6996	101	2.57

Moolec Science currently has a consensus price target of $6.00, indicating a potential upside of 605.88%. As a group, “Biotechnology” companies have a potential upside of 20.97%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Moolec Science is more favorable than its peers.

Profitability

This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,340.74%	-106.26%	-28.29%

Valuation & Earnings

This table compares Moolec Science and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.25
Moolec Science Competitors	$212.91 million	-$18.46 million	-22.07

Moolec Science’s peers have higher revenue, but lower earnings than Moolec Science. Moolec Science is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Moolec Science beats its peers on 7 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.